FUNDAMENTALS · Fundamentals · US Healthcare

Arbutus Biopharma (ABUS) Fundamentals 2026 — P/E 5.2x, Revenue Analysis | SniperIQ

Arbutus Biopharma (ABUS) is a US-listed Healthcare company in Biotechnology with a market capitalization of $864M, trading at $4.38 on the NASDAQ. This SniperIQ fundamentals page covers Arbutus Biopharma's valuation (P/E 5.2x, P/B 3.3x), profitability (net margin 84.0%), revenue (

4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$864M
P/E (TTM)5.2x
Net Margin84.0%
Revenue (FY25)
4M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Arbutus Biopharma's market cap?

Arbutus Biopharma (ABUS) has a market capitalization of approximately $864M, trading at $4.38 on the NASDAQ. Market cap moves with the live share price.

What is Arbutus Biopharma's P/E ratio?

Arbutus Biopharma's trailing twelve-month P/E ratio is 5.2x, with a price-to-book (P/B) of 3.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Arbutus Biopharma?

Arbutus Biopharma runs a net profit margin of 84.0%, a gross margin of 100.0%, and an operating margin of 80.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Arbutus Biopharma generate?

Arbutus Biopharma reported revenue of

4M for fiscal year 2025, with net income of -
4M and earnings per share (EPS) of -0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Arbutus Biopharma pay a dividend?

Arbutus Biopharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Arbutus Biopharma financially healthy?

Arbutus Biopharma carries a debt-to-equity ratio of 0.02x and a current ratio of 54.26x, with a market beta of 0.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Arbutus Biopharma a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Arbutus Biopharma (ABUS) the key facts are: market cap $864M, P/E 5.2x, revenue

4M, 52-week range 3.13-5.38. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Arbutus Biopharma's full fundamentals live

Get Arbutus Biopharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.